Results of a Prospective Study for the Treatment of Retinoblastoma

Cancer

Volumn 100, Issue 4, 2004, Pages 834-842

  Chantada, Guillermo ^a   Fandiño, Adriana ^a   Dávila, María T G ^a   Manzitti, Julio ^a   Raslawski, Elsa ^a   Casak, Sandra ^a   Schvartzman, Enrique ^a  

^a HOSPITAL DE PEDIATRÍA PROF DR JUAN P GARRAHAN   (Argentina)

Author keywords

Advanced disease; Chemotherapy; Radiotherapy; Retinoblastoma

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MESNA; TOPOTECAN; VINCRISTINE;

ARTICLE; AUDIOGRAPHY; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANDIDIASIS; CHOROID; DRUG HYPERSENSITIVITY; DRUG MEGADOSE; ECHOCARDIOGRAPHY; FEMALE; FEVER; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; OPTIC NERVE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RASH; RETINOBLASTOMA; RISK FACTOR; SCLERA; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; ETOPOSIDE; EYE ENUCLEATION; EYE NEOPLASMS; FEMALE; HUMANS; IDARUBICIN; INFANT; MALE; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; OPTIC NERVE NEOPLASMS; PROSPECTIVE STUDIES; RETINOBLASTOMA; RISK FACTORS; SCLERAL DISEASES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VINCRISTINE;

EID: 0842347501     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11952     Document Type: Article

References (20)

1. Schvartzman E, Chantada G, Fandiño A, et al. Results of a stage-based protocol for the treatment of retinoblastoma. J Clin Oncol. 1996;14:1532-1536.
2. Khelfaoui F, Validre P, Auperin A, et al. Histopathologic risk factors in retinoblastoma. A retrospective study of 172 patients treated in a single institution. Cancer. 1996;77:1206-13.
3. Honavar G, Singh A, Shields C, et al. Post enucleation adjuvant therapy in high risk retinoblastoma. Arch Ophthalmol. 2002;20:923-931.
4. Uusitalo M, Van Quill K, Scott I, et al. Evaluation of chemoprophylaxis in patients with unilateral retinoblastoma with high-risk features on histopathologic examination. Arch Ophthalmol. 2001;119:41-48.
5. Chantada GL, de Davila MT, Fandiño A, et al. Retinoblastoma with low risk for extraocular relapse. Ophtalmic Genet. 1999;20:133-140.
6. Namouni F, Doz F, Tanguy ML, et al. High dose chemotherapy with carboplatin, etoposide and cyclophosphamide followed by hematopoietic stem cell rescue in patients with high risk retinoblastoma: an SFOP and SFGM study. Eur J Cancer. 1997;33:2368-2375.
7. Dunkel IJ, Aledo A, Kernan NA, et al. Successful treatment of metastatic retinoblastoma. Cancer. 2000;89:2117-2121.
8. Chantada G, Fandiño A, Casak S, et al. Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 2003;40: 158-161.
9. Antonelli CB, Steinhorst F, de Cassia Braga Ribeiro K, et al. Extraocular retinoblastoma: a 13-year experience. Cancer. 2003;98:1292-1298.
10. Grabowski E, Abramson D. Intraocular and extraocular retinoblastoma. Hematol Oncol Clin North Am. 1987;1:721-735.
11. Demirci H, Eagle RC Jr., Shields CL, Shields JA. Histopathologic findings in eyes with retinoblastoma treated only with chemoreduction. Arch Ophthalmol. 2003;121:1125-1131.
12. Messmer E, Heinrich T, Hopping W, de Sutter E, Havers W, Sauerwein W. Risk factors for metastases in patients with retinoblastoma. Ophthalmology. 1991;98:136-141.
13. Shields C, Shields J, Baez K, Cater J, DePotter P. Optic nerve invasion of retinoblastoma. Metastatic potential and clinical risk factors. Cancer. 1994;73:692-698.
14. Doz F, Neuenshwander S, Plantaz D, et al. Etoposide and carboplatin in extraocular retinoblastoma: a study by the Societé Française d'Oncologie Pédiatrique. J Clin Oncol. 1995;13:902-909.
15. Castello MA, Clerico A, Deb G, Dominici C, Fidani P, Donfrancesco A. High-dose carboplatin in combination with etoposide (JET regimen) for childhood brain tumors. Am J Pediatr Hematol Oncol. 1990;12:297-300.
16. Chantada G, Fandiño A, Mato G, et al. A Phase II window of idarubicin in children with extraocular retinoblastoma. J Clin Oncol. 1999;17:1847-1850.
17. Chan HS, Canton MD, Gallie BL. Chemosensitivity and multidrug resistance to antineoplastic drugs in retinoblastoma cell lines. Anticancer Res. 1989;9:469-474.
18. Verschaugen CF, Jaeckle K, Giovanella B, Knight V, Gilbert BE. Alternative administration of camptothecin analogues. Ann NY Acad Sci. 2000;922:237-246.
19. Fisher PG, Kadan-Lottick NS, Koroner DN. Intrathecal thiotepa: reappraisal of an established therapy. J Pediatr Hematol Oncol. 2002;24:274-278.
20. Schouten-van Meeteren AYN, Moll AC, Imhof SM, Veerman AJP. Chemotherapy for retinoblastoma. An expanding area of clinical research. Med Pediatr Oncol. 2002;38:428-438.